235 related articles for article (PubMed ID: 28518222)
21. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
Michiels JJ; Berneman Z; Schroyens W; De Raeve H
Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
[TBL] [Abstract][Full Text] [Related]
22. Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management.
Tefferi A
Am J Hematol; 2016 Dec; 91(12):1262-1271. PubMed ID: 27870387
[TBL] [Abstract][Full Text] [Related]
23. [Not Available].
Mosca M; Vertenoeil G; Toppaldoddi KR; Plo I; Vainchenker W
Bull Cancer; 2016 Jun; 103(6 Suppl 1):S16-28. PubMed ID: 27494969
[TBL] [Abstract][Full Text] [Related]
24. Minimal residual disease or cure in MPNs? Rationales and perspectives on combination therapy with interferon-alpha2 and ruxolitinib.
Bjørn ME; Hasselbalch HC
Expert Rev Hematol; 2017 May; 10(5):393-404. PubMed ID: 28402197
[TBL] [Abstract][Full Text] [Related]
25. Integrating clinical, morphological, and molecular data to assess prognosis in patients with primary myelofibrosis at diagnosis: A practical approach.
Iurlo A; Elli EM; Palandri F; Cattaneo D; Bossi A; Cortinovis I; Bucelli C; Orofino N; Brioschi F; Auteri G; Bianchi P; Fabris S; Isimbaldi G; Sabattini E; Baldini L; Gianelli U
Hematol Oncol; 2019 Oct; 37(4):424-433. PubMed ID: 31359447
[TBL] [Abstract][Full Text] [Related]
26. Calreticulin mutations in Chinese with primary myelofibrosis.
Li B; Xu J; Wang J; Gale RP; Xu Z; Cui Y; Yang L; Xing R; Ai X; Qin T; Zhang Y; Zhang P; Xiao Z
Haematologica; 2014 Nov; 99(11):1697-700. PubMed ID: 24997152
[TBL] [Abstract][Full Text] [Related]
27. Allogeneic stem cell transplantation in patients with myelofibrosis harboring the MPL mutation.
Mannina D; Gagelmann N; Badbaran A; Ditschkowski M; Bogdanov R; Robin M; Cassinat B; Heuser M; Shahswar R; Thol F; Beelen D; Kröger N
Eur J Haematol; 2019 Dec; 103(6):552-557. PubMed ID: 31446640
[TBL] [Abstract][Full Text] [Related]
28. Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha.
Stauffer Larsen T; Iversen KF; Hansen E; Mathiasen AB; Marcher C; Frederiksen M; Larsen H; Helleberg I; Riley CH; Bjerrum OW; Rønnov-Jessen D; Møller MB; de Stricker K; Vestergaard H; Hasselbalch HC
Leuk Res; 2013 Sep; 37(9):1041-5. PubMed ID: 23827351
[TBL] [Abstract][Full Text] [Related]
29. Autoimmune Myelofibrosis: Clinical Features, Course, and Outcome.
Piatek CI; Vergara-Lluri ME; Pullarkat V; Siddiqi IN; O'Connell C; Brynes RK; Feinstein DI
Acta Haematol; 2017; 138(3):129-137. PubMed ID: 28866671
[TBL] [Abstract][Full Text] [Related]
30. SRSF2 and U2AF1 mutations in primary myelofibrosis are associated with JAK2 and MPL but not calreticulin mutation and may independently reoccur after allogeneic stem cell transplantation.
Bartels S; Lehmann U; Büsche G; Schlue J; Mozer M; Stadler J; Triviai I; Alchalby H; Kröger N; Kreipe H
Leukemia; 2015 Jan; 29(1):253-5. PubMed ID: 25231745
[No Abstract] [Full Text] [Related]
31. Interferon-alpha2 treatment of patients with polycythemia vera and related neoplasms favorably impacts deregulation of oxidative stress genes and antioxidative defense mechanisms.
Skov V; Thomassen M; Kjær L; Ellervik C; Larsen MK; Knudsen TA; Kruse TA; Hasselbalch HC
PLoS One; 2022; 17(6):e0270669. PubMed ID: 35771847
[TBL] [Abstract][Full Text] [Related]
32. A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis.
Tefferi A; Lasho TL; Begna KH; Patnaik MM; Zblewski DL; Finke CM; Laborde RR; Wassie E; Schimek L; Hanson CA; Gangat N; Wang X; Pardanani A
N Engl J Med; 2015 Sep; 373(10):908-19. PubMed ID: 26332545
[TBL] [Abstract][Full Text] [Related]
33. Clinical and molecular response to interferon-α therapy in essential thrombocythemia patients with CALR mutations.
Verger E; Cassinat B; Chauveau A; Dosquet C; Giraudier S; Schlageter MH; Ianotto JC; Yassin MA; Al-Dewik N; Carillo S; Legouffe E; Ugo V; Chomienne C; Kiladjian JJ
Blood; 2015 Dec; 126(24):2585-91. PubMed ID: 26486786
[TBL] [Abstract][Full Text] [Related]
34. CALR mutation, MPL mutation and triple negativity identify patients with the lowest vascular risk in primary myelofibrosis.
Finazzi MC; Carobbio A; Cervantes F; Isola IM; Vannucchi AM; Guglielmelli P; Rambaldi A; Finazzi G; Barosi G; Barbui T
Leukemia; 2015 May; 29(5):1209-10. PubMed ID: 25482134
[No Abstract] [Full Text] [Related]
35. [Interferon-alpha-2b induces molecular responses of patients with polycythemia vera and its post-polycythemic myelofibrosis].
Bai J; Xue YP; Zhang L; Li CH; Fan DM; Li B; Xu SC; Li DP; Sun XJ; Jiang B; Yang RC
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Apr; 19(2):444-9. PubMed ID: 21518505
[TBL] [Abstract][Full Text] [Related]
36. Important Pathologic Considerations for Establishing the Diagnosis of Myelofibrosis.
Salama ME
Hematol Oncol Clin North Am; 2021 Apr; 35(2):267-278. PubMed ID: 33641868
[TBL] [Abstract][Full Text] [Related]
37. Reversible bone marrow aplasia induced by pegylated interferon-α-2a therapy in a patient with primary myelofibrosis.
Mainali NR; Bhatt VR; Kedia S; Krishnamurthy J; Wake LM; Akhtari M
J Oncol Pharm Pract; 2014 Oct; 20(5):386-92. PubMed ID: 24067929
[TBL] [Abstract][Full Text] [Related]
38. Genetically inspired prognostic scoring system (GIPSS) outperforms dynamic international prognostic scoring system (DIPSS) in myelofibrosis patients.
Kuykendall AT; Talati C; Padron E; Sweet K; Sallman D; List AF; Lancet JE; Komrokji RS
Am J Hematol; 2019 Jan; 94(1):87-92. PubMed ID: 30390311
[TBL] [Abstract][Full Text] [Related]
39. Triple-Negative Primary Myelofibrosis: A Bone Marrow Pathology Group Study.
Al-Ghamdi YA; Lake J; Bagg A; Thakral B; Wang SA; Bueso-Ramos C; Masarova L; Verstovsek S; Rogers HJ; Hsi ED; Gralewski JH; Chabot-Richards D; George TI; Rets A; Hasserjian RP; Weinberg OK; Parilla M; Arber DA; Padilla O; Orazi A; Tam W
Mod Pathol; 2023 Mar; 36(3):100016. PubMed ID: 36788093
[TBL] [Abstract][Full Text] [Related]
40. Interferon-alpha for treating polycythemia vera yields improved myelofibrosis-free and overall survival.
Abu-Zeinah G; Krichevsky S; Cruz T; Hoberman G; Jaber D; Savage N; Sosner C; Ritchie EK; Scandura JM; Silver RT
Leukemia; 2021 Sep; 35(9):2592-2601. PubMed ID: 33654206
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
